P130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1

European Journal of Cell Biology

Volumn 90, Issue 2-3, 2011, Pages 237-248

  Tornillo, Giusy ^a   Bisaro, Brigitte ^a   Camacho Leal, Maria del Pilar ^a   Galiè, Mirco ^b   Provero, Paolo ^a   Di Stefano, Paola ^a   Turco, Emilia ^a   Defilippi, Paola ^a   Cabodi, Sara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Breast cancer; ErbB2; P130Cas; Three dimensional culture; Tumour invasion

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CELL CULTURE; DISTANT METASTASIS; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CRK-ASSOCIATED SUBSTRATE PROTEIN; ENZYME ACTIVATION; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; ONCOGENE PROTEIN V-AKT; RAC1 GTP-BINDING PROTEIN; RECEPTOR, ERBB-2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOR SERINE-THREONINE KINASES;

EID: 78649464023     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2010.09.002     Document Type: Article

References (60)

1. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000, 18:2201-2209.
2. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
3. Bouton A.H., Riggins R.B., Bruce-Staskal P.J. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 2001, 20:6448-6458.
4. Brabek J., Constancio S.S., Shin N.Y., Pozzi A., Weaver A.M., Hanks S.K. CAS promotes invasiveness of Src-transformed cells. Oncogene 2004, 44:7406-7415.
5. Cabodi S., Tinnirello A., Di Stefano P., Bisaro B., Ambrosino E., Castellano I., Sapino A., Arisio R., Cavallo F., Forni G., Glukhova M., Silengo L., Altruda F., Turco E., Tarone G., Defilippi P. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006, 66:4672-4680.
6. Cabodi S., Tinnirello A., Bisaro B., Tornillo G., Camacho-Leal M.D.P., Forni G., Cojoca R., Iezzi M., Amici A., Montani M., Eva A., Di Stefano P., Muthuswamy S.K., Tarone G., Turco E., Defilippi P. p130Cas is an essential transducer element in ErbB2 transformation. Faseb J. 2010, [Epub ahead of print].
7. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 2001, 294:1708-1712.
8. Debnath J., Muthuswamy S.K., Brugge J.S. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
9. Defilippi P., Di Stefano P., Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006, 16:257-263.
10. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
11. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
12. Di Stefano P., Damiano L., Cabodi S., Aramu S., Tordella L., Praduroux A., Piva R., Cavallo F., Forni G., Silengo L., Tarone G., Turco E., Defilippi P. p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. Embo J. 2007, 26:2843-2855.
13. Graus-Porta D., Beerli R.R., Hynes N.E. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol. Cell. Biol. 1995, 15:1182-1191.
14. Grimsley C.M., Kinchen J.M., Tosello-Trampont A.C., Brugnera E., Haney L.B., Lu M., Chen Q., Klingele D., Hengartner M.O., Ravichandran K.S. Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration. J. Biol. Chem. 2004, 279:6087-6097.
15. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
16. Holland E.C., Sonenberg N., Pandolfi P.P., Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene 2004, 23:3138-3144.
17. Honda H., Oda H., Nakamoto T., Honda Z., Sakai R., Suzuki T., Saito T., Nakamura K., Nakao K., Ishikawa T., Katsuki M., Yazaki Y., Hirai H. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat. Genet. 1998, 19:361-365.
18. Hsia D.A., Mitra S.K., Hauck C.R., Streblow D.N., Nelson J.A., Ilic D., Huang S., Li E., Nemerow G.R., Leng J., Spencer K.S., Cheresh D.A., Schlaepfer D.D. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 2003, 160:753-767.
19. Hu P., Margolis B., Skolnik E.Y., Lammers R., Ullrich A., Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol. Cell. Biol. 1992, 12:981-990.
20. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
21. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
22. Ignatoski K.M., Maehama T., Markwart S.M., Dixon J.E., Livant D.L., Ethier S.P. ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells. Br. J. Cancer 2000, 82:666-674.
23. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002, 4:648-657.
24. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J. 1996, 15:254-264.
25. Kelleher R.J., Govindarajan A., Jung H.Y., Kang H., Tonegawa S. Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell 2004, 116:467-479.
26. King C.C., Gardiner E.M., Zenke F.T., Bohl B.P., Newton A.C., Hemmings B.A., Bokoch G.M. p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1). J. Biol. Chem. 2000, 275:41201-41209.
27. Klemke R.L., Leng J., Molander R., Brooks P.C., Vuori K., Cheresh D.A. CAS/Crk coupling serves as a " molecular switch" for induction of cell migration. J. Cell Biol. 1998, 140:961-972.
28. Klos K.S., Wyszomierski S.L., Sun M., Tan M., Zhou X., Li P., Yang W., Yin G., Hittelman W.N., Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006, 66:2028-2037.
29. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
30. Lehman J.A., Gomez-Cambronero J. Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem. Biophys. Res. Commun. 2002, 293:463-469.
31. Li E., Stupack D.G., Brown S.L., Klemke R., Schlaepfer D.D., Nemerow G.R. Association of p130CAS with phosphatidylinositol-3-OH kinase mediates adenovirus cell entry. J. Biol. Chem. 2000, 275:14729-14735.
32. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell. Biol. 2009, 5:307-318.
33. Marcotte R., Zhou L., Kim H., Roskelly C.D., Muller W.J. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol. Cell. Biol. 2009, 29:5858-5871.
34. Matsuda M., Mayer B.J., Fukui Y., Hanafusa H. Binding of transforming protein. P47gag-crk, to a broad range of phosphotyrosine-containing proteins. Science 1990, 248:1537-1539.
35. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 2006, 18:516-523.
36. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
37. Muthuswamy S.K., Li D., Lelievre S., Bissell M.J., Brugge J.S. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat. Cell Biol. 2001, 3:785-792.
38. Nanni P., Pupa S.M., Nicoletti G., De Giovanni C., Landuzzi L., Rossi I., Astolfi A., Ricci C., De Vecchi R., Invernizzi A.M., Di Carlo E., Musiani P., Forni G., Menard S., Lollini P.L. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 2000, 87:186-194.
39. Neve R.M., Holbro T., Hynes N.E. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002, 21:4567-4576.
40. O'Neill G.M., Fashena S.J., Golemis E.A. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol. 2000, 10:111-119.
41. Papakonstanti E.A., Stournaras C. Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganisation. Mol. Biol. Cell 2002, 13:2946-2962.
42. Pearson R.B., Dennis P.B., Han J.W., Williamson N.A., Kozma S.C., Wettenhall R.E., Thomas G. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. Embo J. 1995, 14:5279-5287.
43. Reynolds A.B., Kanner S.B., Wang H.C., Parsons J.T. Stable association of activated pp60src with two tyrosine-phosphorylated cellular proteins. Mol. Cell. Biol. 1989, 9:3951-3958.
44. Riggins R.B., Quilliam L.A., Bouton A.H. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J. Biol. Chem. 2003, 278:28264-28273.
45. Saitoh M., Pullen N., Brennan P., Cantrell D., Dennis P.B., Thomas G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J. Biol. Chem. 2002, 277:20104-20112.
46. Sekulic A., Hudson C.C., Homme J.L., Yin P., Otterness D.M., Karnitz L.M., Abraham R.T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000, 60:3504-3513.
47. Seton-Rogers S.E., Brugge J.S. ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?. Cell Cycle 2004, 5:597-600.
48. Sharma S.V., Settleman J. ErbBs in lung cancer. Exp. Cell Res. 2009, 315:557-571.
49. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
50. Spencer K.S., Graus-Porta D., Leng J., Hynes N.E., Klemke R.L. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J. Cell Biol. 2000, 148:385-397.
51. Stupack D.G., Cho S.Y., Klemke R.L. Molecular signaling mechanisms of cell migration and invasion. Immunol. Res. 2000, 21:83-88.
52. Ta H.Q., Thomas K.S., Schrecengost R.S., Bouton A.H. A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res. 2008, 68:8796-8804.
53. Thomas G. p70s6k/p85s6k: mechanism of activation, effects of rapamycin and role in mitogenesis. Biochem. Soc. Trans. 1993, 21:901-904.
54. Tikhmyanova N., Little J.L., Golemis E.A. CAS proteins in normal and pathological cell growth control. Cell. Mol. Life. Sci. 2009.
55. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347:1999-2009.
56. van der Flier S., Brinkman A., Look M.P., Kok E.M., Meijer-van Gelder M.E., Klijn J.G., Dorssers L.C., Foekens J.A. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J. Natl. Cancer Inst. 2000, 92:120-127.
57. Welch H.C., Coadwell W.J., Stephens L.R., Hawkins P.T. Phosphoinositide 3-kinase-dependent activation of Rac. Febs Lett. 2003, 546:93-97.
58. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2:127-137.
59. Yu A.E., Hewitt R.E., Connor E.W., Stetler-Stevenson W.G. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 1997, 11:229-244.
60. Zhou H.Y., Wong A.S. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006, 147:2557-2566.